Dr. Chandler Park discusses the importance of genetic testing and personalized care in patients with genitourinary cancers.

Explore how a high omega-3, low omega-6 diet could help slow prostate cancer progression and improve overall prostate health.

Casdatifan, a HIF-2α inhibitor, shows early clinical activity and good tolerance in patients with previously treated clear cell renal cell carcinoma.

GMP Human FGF-8b Protein (Cat. No. GMP-FGBH16) and Human FGF-8b Protein, Premium Grade (Cat. No. FGB-H5115) exhibit similar ...

Intended setting of use for genitourinary cancer drug approvals by tumor type, 2020-2024. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This abstract does not ...

Evaluating cost-effectiveness in the evolving treatment landscape for metastatic urothelial carcinoma.

NEW YORK--(BUSINESS WIRE)--Flatiron Health today announced its planned presence at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), including three accepted ...

FDA approves vimseltinib for tenosynovial giant cell tumor and a triplet for R/R LBCL, plus the latest from ASCO GU 2025.

First real-world outcomes data for ADSTILADRIN® (nadofaragene firadenovec-vncg) to be presented at 2025 ASCO Genitourinary ...

Cade, Telix Group Chief Medical Officer, said, “Telix will feature in four presentations at this year’s ASCO GU, which showcase the depth and differentiation of our therapeutic urologic pipeline, ...

Dr. Laurence Albiges discusses triplet therapies, highlighting which patients with RCC may garner the most benefit with this treatment intensification.